Academic Journal

Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration

التفاصيل البيبلوغرافية
العنوان: Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration
المؤلفون: Banella, C, Ginevrino, M, Catalano, G, Fabiani, E, Falconi, G, Divona, M, Curzi, P, Panetta, P, Voso, M T, Noguera, N I
المساهمون: Banella, C, Ginevrino, M, Catalano, G, Fabiani, E, Falconi, G, Divona, M, Curzi, P, Panetta, P, Voso, Mt, Noguera, Ni
بيانات النشر: Elsevier
SA
سنة النشر: 2020
المجموعة: Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca
مصطلحات موضوعية: Acute myeloid leukemia, Aneuploidy, FGFR3–TACC3, Glioblastoma, Myelodysplastic syndromes, Settore MED/15 - MALATTIE DEL SANGUE
الوصف: FGFR-TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR-TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3-TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.
نوع الوثيقة: article in journal/newspaper
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/32199932; volume:-; issue:-; firstpage:1; lastpage:6; numberofpages:6; journal:HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY; http://hdl.handle.net/2108/257121; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85082087376
DOI: 10.1016/j.hemonc.2020.02.005
الاتاحة: http://hdl.handle.net/2108/257121
https://doi.org/10.1016/j.hemonc.2020.02.005
Rights: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.A5336F55
قاعدة البيانات: BASE
الوصف
DOI:10.1016/j.hemonc.2020.02.005